Fast relief from hives and itch in a pill—with results measured at week 12

Proven relief from chronic hives with no known external triggers

You deserve a chance to find relief from constant hives and itch. RHAPSIDO^® (remibrutinib) could make that happen.

In one clinical study

Results at week 12

Hives severity (HSS7) reduced 10.47 points with RHAPSIDO vs 6.00 with placebo on average from the start of the study.

Itch severity (ISS7) reduced 8.95 points with RHAPSIDO vs 5.72 with placebo on average from the start of the study.

*These results were calculated from observed data. No statistical analyses were done and conclusions should not be drawn.

Results at week 2

Approximately 5x as many people had well-controlled hives and itch (UAS7 less than or equal to 6) at week 2 with RHAPSIDO (30 percent vs 5.9 percent with placebo).

RHAPSIDO was studied in 2 identical clinical trials in adults (≥18 years of age) with chronic hives with no known external triggers who continued to have symptoms while taking antihistamines. All participants stayed on antihistamines while also taking either RHAPSIDO or placebo (in the trial presented: RHAPSIDO, n=297; placebo, n=153). Placebo does not contain any active medicine. Results were calculated based on least squares (LS) mean change from baseline and were similar between both trials.

How hives and itch were measured:

Participants rated hives and itch twice a day on 0 to 3 scales: the Hives Severity Score (HSS7) and the Itch Severity Score (ISS7). The worse the symptom, the higher the score
The average daily ratings were added up each week and compared to their starting scores
Scores for hives (HSS7) and itch (ISS7) can be combined into the Urticaria Activity Score (UAS7), which measures overall symptom severity. The total can range from 0 to 42, where 6 or less is well-controlled symptoms and 28 and over is severe symptoms